Keybanc analyst Josh Beck downgrades Vtex (NYSE:VTEX) from Overweight to Sector Weight.
GlaxoSmithKline’s Anemia Candidate Shows Promise In Late-Stage Studies
GlaxoSmithKline Plc (NYSE:GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat,…